Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 11:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Evaluating Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT

NCT00586274
View directory record Official record
Conditions
FANCONI ANEMIA
Interventions
CD34 selected haploidentical PBSCT, Fludarabine, T cell infusion, Campath 1h, anti-CD45
Procedure · Drug · Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 64 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2009
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Sep 13, 2026, 11:22 AM EDT
Completed Phase 1 Interventional

Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy

NCT02058550
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Radiation Toxicity, Vaginal Cancer
Interventions
survey administration, computer-assisted intervention, telephone-based intervention
Other · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Sep 13, 2026, 11:22 AM EDT
Withdrawn Phase 2 Interventional

Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma

NCT03014804
View directory record Official record
Conditions
Giant Cell Glioblastoma, Gliosarcoma, Oligodendroglioma, Recurrent Glioblastoma, Small Cell Glioblastoma
Interventions
autologous dendritic cells pulsed with tumor lysate antigen Vaccine, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Biological · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Sep 13, 2026, 11:22 AM EDT
Active, not recruiting Phase 1 Interventional

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

NCT04041050
View directory record Official record
Conditions
Myeloproliferative Neoplasm
Interventions
Navitoclax, Ruxolitinib, Celecoxib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
12
States / cities
Duarte, California • Fullerton, California • La Jolla, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Sep 13, 2026, 11:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia

NCT06364774
View directory record Official record
Conditions
Beta-Thalassemia
Interventions
ALS20
Biological
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 13, 2026, 11:22 AM EDT
Withdrawn Phase 1 Interventional

Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma

NCT04466475
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Melphalan, Peripheral Blood Stem Cell Transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Sep 13, 2026, 11:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD

NCT02498301
View directory record Official record
Conditions
Travelers' Diarrhea, Functional Bowel Disorders, Reactive Arthritis
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
5
States / cities
San Diego, California • Honolulu, Hawaii • Marine Corps Base Camp Lejeune, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Sep 13, 2026, 11:22 AM EDT
Enrolling by invitation No phase listed Observational

Cervical Interbody Implant Study

NCT04689854
View directory record Official record
Conditions
Degenerative Disc Disease, Cervical Spinal Instability
Interventions
Not listed
Lead sponsor
NuVasive
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
Orange, California • Hartford, Connecticut • Somerville, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 13, 2026, 11:22 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

NCT03140722
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
vadadustat, epoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
18
States / cities
Bakersfield, California • Elk Grove, California • Encino, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 13, 2026, 11:22 AM EDT
Terminated Not applicable Interventional

Study of Electro-kinetically Modified Water for the Treatment of Pain Associated With Endometriosis

NCT02523794
View directory record Official record
Conditions
Pelvic Pain
Interventions
Electro-kinetically Modified Water, Placebo
Other
Lead sponsor
Revalesio Corporation
Industry
Eligibility
16 Years to 49 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Sep 13, 2026, 11:22 AM EDT
Withdrawn Phase 2 Interventional

Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

NCT00485966
View directory record Official record
Conditions
B-Cell Chronic Lymphocytic Leukemia
Interventions
CX-3543
Drug
Lead sponsor
Cylene Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Scottsdale, Arizona • Beverly Hills, California • Albuquerque, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2008 · Synced Sep 13, 2026, 11:22 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Assessing Gingivitis and Plaque From a Marketed Toothpaste

NCT07158112
View directory record Official record
Conditions
Gingivitis
Interventions
Stannous Fluoride Dentifrice, Test Stannous Fluoride Dentifrice, Sodium monofluorophosphate dentifrice
Drug
Lead sponsor
Procter and Gamble
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Whitter, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 13, 2026, 11:22 AM EDT
Terminated Phase 2 Interventional Results available

Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

NCT03452527
View directory record Official record
Conditions
Choroidal Neovascularization, Wet Macular Degeneration
Interventions
ICON-1, aflibercept
Biological
Lead sponsor
Iconic Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
8
States / cities
Beverly Hills, California • Santa Ana, California • Syracuse, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 13, 2026, 11:22 AM EDT
Terminated No phase listed Observational

Evaluating the Effects of Surgical and Non-Surgical Treatment Options in People With Emphysema

NCT00675454
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Emphysema
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
35 Years to 90 Years
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Sep 13, 2026, 11:22 AM EDT
Active, not recruiting Not applicable Interventional

Evaluating the Impact of Telehealth-Based ASD Assessments and Supports on Child and Caregiver Outcomes

NCT04881656
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Help is in Your Hands
Other
Lead sponsor
University of California, Davis
Other
Eligibility
6 Months to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 13, 2026, 11:22 AM EDT
Enrolling by invitation Not applicable Interventional

HIFEM Technology for Post-Radical Prostatectomy and Post-Holmium Laser Prostate Surgery

NCT06803602
View directory record Official record
Conditions
Holmium Laser Prostate Surgery, Radical Prostatectomy
Interventions
EMSELLA®, Sham Comparator Device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
2,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 13, 2026, 11:22 AM EDT
Recruiting Not applicable Interventional

Dosing rTMS for Depression Post-SCI

NCT05553353
View directory record Official record
Conditions
Spinal Cord Injuries, Depression, Depressive Disorder, Major
Interventions
repetitive transcranial magnetic stimulation--Active, repetitive transcranial magnetic stimulation--Sham
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 13, 2026, 11:22 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

NCT04798339
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Canakinumab Injection, Darbepoetin Alfa
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Tampa, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 13, 2026, 11:22 AM EDT
Completed Phase 2 Interventional

A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris

NCT01194375
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Low Strength IDP-107, High Strength IDP-107, Placebo
Drug
Lead sponsor
Dow Pharmaceutical Sciences
Industry
Eligibility
12 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
17
States / cities
Oceanside, California • Denver, Colorado • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2012 · Synced Sep 13, 2026, 11:22 AM EDT
Completed Phase 2 Interventional

Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00425646
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, imatinib mesylate
Biological · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 5, 2013 · Synced Sep 13, 2026, 11:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

In-Home Technology for Dementia Caregivers

NCT03828383
View directory record Official record
Conditions
Dementia, Alzheimer's Disease, Frontotemporal Dementia
Interventions
In-home technology, Limited in-home technology
Device
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
5
States / cities
Berkeley, California • Los Angeles, California • Orange, California + 2 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Sep 13, 2026, 11:22 AM EDT
Completed Phase 2 Interventional

Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas

NCT00134641
View directory record Official record
Conditions
Sarcoma, Soft Tissue
Interventions
gemcitabine, vinorelbine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2007 · Synced Sep 13, 2026, 11:22 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of IGM-6268 in Healthy Volunteers

NCT05160402
View directory record Official record
Conditions
Healthy Volunteers
Interventions
IGM-6268, Placebo
Drug
Lead sponsor
IGM Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Sep 13, 2026, 11:22 AM EDT
Recruiting Phase 4 Interventional

Efficacy of Placental Membrane Dressings in Accelerating Diabetic Foot Healing

NCT07326553
View directory record Official record
Conditions
Diabete Mellitus, Foot Ulcer Chronic
Interventions
Placental Membrane
Biological
Lead sponsor
BioXTek
Industry
Eligibility
45 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Phoenix, Arizona • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 13, 2026, 11:22 AM EDT